Evaluation of the effects of ß1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal women

BETÜL YAVUZ KELEŞ
MELTEM VURAL
BURCU ÖNDER
KADRİYE ÖNEŞ

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
KELEŞ, BETÜL YAVUZ; VURAL, MELTEM; ÖNDER, BURCU; and ÖNEŞ, KADRİYE (2020) "Evaluation of the effects of ß1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal women," Turkish Journal of Medical Sciences: Vol. 50: No. 4, Article 46. https://doi.org/10.3906/sag-1909-187
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss4/46

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
1. Introduction.
Osteoporosis is a disease with worldwide prevalence. It decreases bone mass and strength, thereby resulting in fractures and primarily affects postmenopausal women [1–3]. Almost, 40% postmenopausal women have osteoporosis [4]. A deterioration in bone mass and strength with aging is an expected situation besides the several factors that may affect bone mass and strength, such as inflammation, endocrinological and metabolic disorders and some drugs [5–7].

Recent studies have shown that the sympathetic nervous system significantly affects bone metabolism [8–12]. Typically, sympathetic activation is considered to contribute to bone loss [13]. This effect was believed to be mainly mediated by β_2_ adrenergic receptors [9–11]. However, some researchers have shown that β_1_ and β_3_ adrenergic receptors are also present in the human periosteal osteoblasts and human osteosarcoma-derived cells [14].

Beta-blockers (BBs), especially β_1_-selective BBs, are the commonly used sympatholytic agents and find use in several cardiovascular diseases such as hypertension, arrhythmias, myocardial infarction, congestive heart failure and angina pectoris [15]. Osteoporosis and cardiovascular diseases often occur together during the postmenopausal period [16]. Several studies have investigated the effects of nonselective BBs on fracture risk and bone mineral density (BMD), albeit with conflicting results [16–20]. In contrast, some researchers have found β_1_ receptors in the human periosteal osteoblasts, which makes it imperative to determine the effects of β_1_-selective BBs on bone health. In a previous study, it was concluded that metoprolol prevented the bone loss in ovariectomized rats [21].

This study aimed to investigate the effects of β_1_-selective BBs on BMD, fragility fracture and the 10-year predicted probability of major osteoporotic and hip fractures. To our knowledge, no investigation has yet been done regarding the 10-year predicted probability of major osteoporotic and hip fractures in postmenopausal women using β_1_-selective BBs.
2. Materials and methods

2.1. Study design and subjects
This cross-sectional study has been approved by the local ethics committee of Bakırköy Dr. Sadi Konuk Training Hospital (2018/57) and has been performed per the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from the subjects.

Postmenopausal women who were admitted to the outpatient clinic Istanbul Physical Medicine and Rehabilitation Training and Research Hospital between January 2018 and September 2018 were evaluated for this study. Women who had not menstruated for at least 1 year were considered menopausal as per the definition of the World Health Organization [22].

Criteria for exclusion were as follows: Older than 65 years, abnormality in laboratory tests (complete blood count, serum creatinine, calcium, phosphorus), endocrine disorders, chronic liver disease, history of steroid use (at any time more than 3 months), anticonvulsant and anticoagulant drug use, acute and chronic infectious disease, inflammatory disease, history of malignancy, secondary osteoporosis and undergoing treatment for osteoporosis. Because of the potential impact on bone turnover, patients who used a drug for more than 3 months besides \( \beta_1 \)-selective BBs were excluded from the study. The study comprised 2 groups: BB and control groups. The control group included postmenopausal women who were age- and menopause duration-matched with those of the BB group and had no history of BBs usage. The minimum BB usage period was determined as 6 months in the BB group and all women in BB were using \( \beta_1 \)-selective BBs when included in the study.

2.2. Methods

2.2.1. Demographic characteristics
Age (year), height (cm), weight (kg), body mass index (BMI, kg/m\(^2\)) and time after the last menstruation cycle (year) of the participants were recorded. Additionally, the participants were also asked about their smoking status, alcohol intake, regular exercise, previous fragility fracture with the timing of the fracture (premenopausal or postmenopausal) and history of hip fracture in the family. Fractures that occurred during childhood were not recorded. An exercise regime of more than 30 min at least thrice a week was considered as regular exercise. The period of \( \beta_1 \)-selective BBs use was recorded for patients of BBs group per the information received from them.

2.2.2. Bone mineral density
The BMD was measured at the lumbar spine and femur by using dual-energy X-ray absorptiometry (DPX-LUNAR 74400). Lumbar spine (L1-4, L2-4), femur neck and femur total T-scores and BMD (g/cm\(^2\)) were recorded.

2.2.3. Fracture risk assessment tool (FRAX)
FRAX calculates the 10-year fracture probability of a major osteoporotic (FRAX-major) and hip fracture (FRAX-hip) by using some variables (age, BMI, previous fracture, parent hip fracture, current smoking, glucocorticoid use, alcohol consumption, rheumatoid arthritis and secondary osteoporosis). FRAX-hip and FRAX-major of subjects were calculated using the Turkish version of the FRAX assessment tool [23, 24].

2.3. Sample size
Power analysis was performed with reference to a previous study to determine the minimum number of participants planned to be included in the study [25]. Minimum 26 participants for each group were needed to achieve the effect size (\( d = 0.84 \)) of the previous study with alpha error probability of 0.05 and 80% power.

2.4. Statistical analysis
Statistical studies were performed using the MedCalc software, version 18.11.3. Descriptive statistics were shown as the mean ± standard deviation for continuous variables, and nominal variables were presented as the number of cases and percentages (%). Normality was tested by Kolmogorov-Smirnov test for continuous variables. Intergroup comparisons of the various parameters were performed using the independent-samples t-test and the chi-square test wherever applicable. Pearson method was used to calculate the correlation rho. A value of \( P < 0.05 \) was considered statistically significant.

3. Results
This study evaluated 215 postmenopausal women, of which 60 women who met the study criteria were included. The BB and control group each comprised 30 subjects with a mean age of 57.86 ± 5.66 in the BB group and 55.41 ± 5.9 in the control group. Mean cessation of menstruation was 9.14 ± 5.73 years in BB group and 9.45 ± 6.96 years in the control group. The average period of \( \beta_1 \)-selective BBs use was 42.6 ± 36.7 months. No statistically significant difference was found in the mean age, cessation of menstruation, weight, height, BMI, smoking and regular exercise. Alcohol consumption was absent in both groups. There were 2 subjects in the BB group and 6 in the control group who had a previous fracture (\( P = 0.132 \)). The previous fractures noted in the BB group were that of the foot and costa. The control group had prior fractures in the hip, proximal tibia, proximal humerus, foot and two in the forearm. All these fractures occurred during the postmenopausal period. The fractures in the BB group occurred during BB usage. The demographic and general features of each group are shown in Table 1.

Lumbar spine (L1-4 and L2-4) BMD values were significantly higher in BB group compared with the control group (\( P = 0.015 \) and \( P = 0.025 \), respectively). Additionally, T-scores of lumbar spine (L1-4 and L2-4) and femur total
were significantly higher in BB group (P = 0.02, P = 0.016 and P = 0.006, respectively) compared with the control group. No statistically significant intergroup difference was found regarding the 10-year fracture probability of a major osteoporotic and hip fracture. Table 2 shows the comparison of BMDs, T-scores, FRAX-major and FRAX-hip of the 2 groups.

4. Discussion
In this study, we investigated the effects of \( \beta_1 \)-selective BB use on bone health in postmenopausal women. Based on the study results, \( \beta_1 \)-selective BB use was associated with higher BMD in the lumbar region. Additionally, the lumbar and femoral total T-scores were better in the BB group compared with the control group.

Farr et al. showed that sympathetic activity was 2–4-fold higher in postmenopausal women than in premenopausal women [26]. Furthermore, evidence suggests that sympathetic activity has a deleterious effect on bones [27]. Takeda et al. showed that leptin regulates bone formation through the sympathetic nervous system and the systemic administration of nonselective BBs increases bone mass [8]. Furthermore, they reported that leptin affects the osteoblasts through \( \beta_2 \) adrenergic receptors. Subsequent studies have shown the presence of \( \beta_1 \) and \( \beta_3 \) adrenergic receptors in the bone [14].

Zhang et al. investigated the effects of metoprolol (\( \beta_1 \)-selective BB) on osteoblasts in ovariectomised rats. They concluded that metoprolol prevents oestrogen deficiency-induced bone loss and recommended metoprolol as an

Table 1. The demographic features of the groups.

| Age (years) | 57.9 ± 5.7 | 55.4 ± 5.9 | 0.113* |
| Weight (kg) | 75.6 ± 9.9 | 69.9 ± 2.2 | 0.097* |
| Height (cm) | 154.8 ± 5.5 | 156.2 ± 4.5 | 0.366 |
| BMI (kg/m²) | 31.4 ± 4.3 | 28.7 ± 4.4 | 0.056* |
| Cessation of menstruation (years) | 9.1 ± 5.7 | 9.4 ± 6.9 | 0.857* |
| Smoking (%) | 10 | 20 | 0.138k |
| Alcohol (%) | 0 | 0 | |
| Previous fracture (n) | 2 | 6 | 0.132b |
| Regular exercise (%) | 16.6 | 3.3 | 0.087b |

BMI: Body mass index, (mean ± SD), * Independent-samples t-test, * Chi-square test. *P < 0.05.

Table 1. The demographic features of the groups.

| | BBs group (N = 30) | Control group (N = 30) | p |
|---|---|---|---|
| L1-4 BMD (g/cm²) | 0.9±0.2 | 0.8 ± 0.1 | 0.015* |
| L2-4 BMD (g/cm²) | 0.9 ± 0.2 | 0.8 ± 0.1 | 0.025* |
| Femur neck BMD (g/cm²) | 0.8 ± 0.0 | 0.8 ± 0.1 | 0.296 |
| Femur total BMD (g/cm²) | 0.9 ± 0.0 | 0.9 ± 0.1 | 0.065 |
| L1-4 T-score | -1.4 ± 1.3 | -2.1 ± 0.7 | 0.020* |
| L2-4 T-score | -1.3 ± 1.4 | -2.1 ± 0.7 | 0.016* |
| Femur neck T-score | -0.5 ± 0.9 | -0.9 ± 0.7 | 0.141 |
| Femur total T-Score | -0.4 ± 0.6 | -1 ± 0.8 | 0.006* |
| Frax-major fracture (%) | 4.7 ± 2.0 | 5.3 ± 2.7 | 0.412 |
| Frax-hip fracture (%) | 0.5 ± 0.4 | 0.9 ± 0.8 | 0.078 |

*P < 0.05. Values are expressed as mean ± standard deviation, BMD: Bone mineral density, FRAX: Fracture risk assessment tool.
alternative treatment for postmenopausal osteoporosis in hypertensive patients [21]. Furthermore, Khosla et al. showed that the trabecular bone volume and trabecular number were significantly better in the patients using $\beta_1$-selective BB group, but there was no significant difference in cortical bone parameters [28]. Concordant with this result, our BB group showed better BMD values in the lumbar region where the trabecular bone is predominant. In contrast, no significant difference was detected in the BMD and T-score of the femoral neck where the cortical bone is predominant. Another study has also shown a negative correlation between sympathetic activity and trabecular bone [21].

In this study, we also evaluated the 10-year probability of a major osteoporotic and hip fracture in participants by using FRAX. Based on our results, the mean value of the 10-year predicted probability of major fracture was 4.69% in the BB group and 5.35% in the control group. Even though the mean value of major hip fracture risk was 0.48% in the BB group and 0.87% in the control group, the intergroup difference was not statistically significant. Tuzun et al. found the mean 10-year major osteoporotic fracture probability to be 6.0% and that of hip fracture to be 2% in Turkish population aged 50 years or more [29]. The major osteoporotic and hip fracture probabilities in postmenopausal women were determined as 5.5% and 0.9%, respectively, per a previous study result, which is similar to the FRAX results of our control group [30].

Furthermore, there were 2 subjects with a previous fragility fracture in the BB group and 6 subjects in the control group. Considering this result, the fracture rate in the control group seems slightly higher, but the intergroup difference was not statistically significant. The findings of a meta-analysis that investigated the effects of BBs on fracture suggested that the risk of fracture is about 15% lower in patients treated with BB and this effect has been mostly attributed to $\beta_1$-selective BB by authors [15].

To our knowledge, the 10-year predicted probability of major osteoporotic and hip fracture was not investigated before in postmenopausal women using $\beta_1$-selective BBs, which is a significant strength of our study. Moreover, we excluded the subjects who took other drugs besides BBs to eliminate their effects on bone, which is another advantage of the present study. Even though $\beta_1$-selective BBs are commonly used drugs, it was some hard to find the subjects who only used $\beta_1$-selective BBs without other cardiovascular and other medications because we wanted to evaluate only the effects of $\beta_1$-selective BB on the bone. Notably, most of the women using $\beta_1$-selective BBs were also taking other drugs.

Nonetheless, this study has some limitations. First, this was a cross-sectional study. Therefore, further prospective, randomised, controlled studies in the future may provide health professionals with more information regarding fracture risk and BMD in subjects using $\beta_1$-selective BBs. Second, subjects who regularly exercised were more likely to be in the BB group, although there was no statistically significant difference. However, this may have positively contributed to BMD.

In conclusion, $\beta_1$-selective BB usage was associated with higher BMD at the lumbar region in postmenopausal women. The dual beneficial effects of $\beta_1$-selective BBs on both the cardiovascular and skeletal systems in postmenopausal women can be advantageous for patients who are required to use these drugs for a long time or sometimes for a lifetime.

Acknowledgments/Disclaimers
This study was presented in Turkish Rheumatology Congress with international participation 2018. The authors received no financial support for the research and/or authorship of this article. The authors would like to thank Enago (www.enago.com) for the English language review.

Conflict of interest
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

References
1. Black DM, Rosen CJ. Postmenopausal osteoporosis. The New England Journal of Medicine 2016; 374 (3): 254-262. doi: 10.1056/NEJMc1513724
2. Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women's Health Initiative. Seminars in Reproductive Medicine 2014; 32 (6): 454-62. doi: 10.1002/art.36611
3. Diab DL, Watts NB. Postmenopausal osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity 2013; 20 (6): 501-509. doi: 10.1097/01.med.0000436194.10599.94
4. Qui Y, Yang W, Wang QYan S, Li B et al. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. Archives of Osteoporosis 2018; 13 (1): 1-8. doi: 10.1007/s11657-018-0534-5
5. Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research 2003; 18 (4): 784-790. doi: 10.1359/jbmr.2003.18.4.784
6. Puth MT, Klaschik M, Schmid M, Weckbecker K, Münster E. Prevalence and comorbidity of osteoporosis— a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskeletal Disorders 2018; 19 (1): 144.

7. Hant FN, Bolster MB. Drugs that may harm bone: mitigating the risk. Cleveland Clinic Journal of Medicine 2016; 83 (4): 281-288. doi: 10.3949/ccjm.83a.15066

8. Takeda S, Elefteriou F, Lavasseur R, Liu X, Zhao L et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111 (3): 305-317. doi: 10.1016/s0092-8674(02)01049-8

9. Reid IR, Lucas J, Wattie D, Horne A, Bolland M et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism 2005; 90 (9): 5212-5216. doi: 10.1210/jc.2005-0573

10. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100 (2): 197-207. doi: 10.1016/s0092-8674(00)81585-8

11. Solomon DH, Ruppert K, Zhao Z, Liang Y, Kuo IH et al. Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study. Osteoporosis International 2016; 27 (3): 1181-1189. doi: 10.1007/s00198-015-3332-6

12. Ağcaşayak KS, Güven S, Kopolar M, Güneş N, Atalay Y et al. Long-term effects of antihypertensive medications on bone mineral density in men older than 55 years. Clinical Interventions in Aging 2014; 9: 174-195. doi: 10.14310/horm.2002.1308

13. Toulis KA, Anastasilakis AD, Polyzos SA, Makras P. Targeting the osteoblast; approved and experimental anabolic agents for the treatment of osteoporosis. Hormones (Athens) 2011;10 (3): 174-195. doi: 10.14310/horm.2002.1308

14. Togari A, Araki M, Mizutani S, Koshihara Y, Nagatsu Y. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neuroscience Letters 1997; 233 (2-3): 125-128. doi: 10.1016/s0304-3908(97)00649-6

15. Toulis KA, Hemmeng K, Stergianos S, Niranthurakumar K, Bilezikian J. β-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporosis International 2014; 25 (1): 121-129. doi: 10.1007/s00198-013-249

16. Sosa M, Saavedra P, Gomez de Tejeda MJ, Mosquera J, Pérez-Cano R et al. Beta blocker use associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clinical and Experimental Research 2011; 23 (2):112-117. doi: 10.3275/7041

17. Yang S, Nguyen ND, Eismen JA, Nguyen TV. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2012; 51 (5): 969-974. doi: 10.1016/j.bone.2010.10.170

18. Song HJ, Lee J, Kim YJ, Jung SY, Kim HJ et al. Beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients. Bone 2012; 51 (6): 1008-1015. doi: 10.1016/j.bone.2012.08.126

19. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Mendo M et al. Effect of beta-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine 2007; 74 (3): 259-262. doi: 10.1016/j.jbspin.2006.09.015

20. Barzilay JI, Davis BR, Pressel SL, Barzilay JI, Davis BR et al. The impact of antihypertensive medications on bone mineral density and fracture rate. Current Cardiology Reports 2017; 19 (9): 1-9. doi: 10.1007/s11886-017-0888-0

21. Zang Y, Tan Q, Ma X, Zhao X, Lei W. Osteogenic actions of metoprolol in an ovariectomized rat model of menopause. Menopause 2016; 23 (9): 1019-1025. doi: 10.1097/GME.0000000000000680

22. WHO Scientific Group on Research on the Menopause in the 1990s (1994 : Geneva, Switzerland) & World Health Organization,World Health Organization technical report series 1996; 866: 1-107.

23. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M et al. Turkish Osteoporosis Society. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRAC'TURK study. Osteoporosis International 2012; 23 (3): 949-955. doi: 10.1007/s00198-011-1655-5

24. Koçyiğit F, Acar M, Baydar M, Kuyucu E, Koçyiğit A. Would FRAX define the high fracture risk if the patients were evaluated the day before hip fracture? Turkish Journal of Physical Medicine and Rehabilitation 2015; 61 (4): 339-343. doi: 10.5152/tfrzd.2015.32549

25. Türker S, Karatousun V, Gunal I. Beta-blockers increase bone mineral density. Clinical Orthopaedics and Related Research 2006; 443: 73-74. doi: 10.1097/01. bco.0000200242.52802.6d

26. Farr JN, Charkoudian N, Barnes JN, Monroe DG, McCready LK et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin. The Journal of Clinical Endocrinology & Metabolism 2012; 97 (11): 4219-4227. doi: 10.1210/jc.2012-2381.

27. Lambert E, Phillips S, Tursunalieva E, Eikels N, Sari C et al. Inverse association between sympathetic nervous system activity and bone mass in middle aged overweight individuals. Bone 2018; 11: 123-128. doi: 10.1016/j. bone.2018.03.025

28. Khosla S, Drake MT, Volkman TL, Thicke BS, Achenbach SJ et al. Sympathetic β-adrenergic signaling contributes to regulation of bone metabolism. Journal of Clinical Investigation 2018; 128 (11): 4832-4842. doi: 10.1172/JCI122151

29. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Johansson H et al. The impact of a FRAX-based intervention threshold in Turkey: The FRAX-TURK study. Archives of Osteoporosis 2012; 7: 229-235. doi: 10.1007/s11657-012-0101-4

30. OlmezSarikaya N, KaparYavasi S, Tan G, Satiroglu S, Yildiz AH et al. Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clinical Rheumatology 2014; 33 (12): 1785-1789. doi: 10.1007/s10067-014-2491-8